Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope
Saved in:
| Main Authors: | Lisa Argnani, Beatrice Casadei, Pier Luigi Zinzani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-03-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01246-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01) -
Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient
by: Pier Luigi Zinzani, et al.
Published: (2020-06-01) -
Advance in chimeric antigen receptor T therapy in autoimmune diseases
by: Xiaolan Ji, et al.
Published: (2025-03-01) -
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome
by: Serena De Matteis, et al.
Published: (2024-12-01) -
The potential of chimeric antigen receptor -T cell therapy for endocrine cancer
by: Ruonan Yu, et al.
Published: (2025-04-01)